300942 Stock Overview
Develops and sells rapid testing instruments and reagents in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Shenzhen Bioeasy Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.02 |
| 52 Week High | CN¥16.88 |
| 52 Week Low | CN¥5.25 |
| Beta | 0.61 |
| 11 Month Change | -18.10% |
| 3 Month Change | -28.16% |
| 1 Year Change | -51.96% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300942 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | 5.4% | -1.7% | 0.4% |
| 1Y | -52.0% | -19.3% | -17.8% |
Return vs Industry: 300942 underperformed the CN Medical Equipment industry which returned -19.3% over the past year.
Return vs Market: 300942 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 300942 volatility | |
|---|---|
| 300942 Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 300942's share price has been volatile over the past 3 months.
Volatility Over Time: 300942's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 389 | n/a | www.bioeasy.com |
Shenzhen Bioeasy Biotechnology Co., Ltd. develops and sells rapid testing instruments and reagents in China. The company offers cereals and feed, milk antibiotic, meat and seafood, honey antibiotic, and pesticides rapid test kits. It also offers veterinary, coronavirus, and DNA / RNA extraction kits, as well as provides drug of abuse screening tests.
Shenzhen Bioeasy Biotechnology Co., Ltd. Fundamentals Summary
| 300942 fundamental statistics | |
|---|---|
| Market cap | CN¥2.41b |
| Earnings (TTM) | -CN¥163.96m |
| Revenue (TTM) | CN¥229.87m |
10.7x
P/S Ratio-15.0x
P/E RatioIs 300942 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300942 income statement (TTM) | |
|---|---|
| Revenue | CN¥229.87m |
| Cost of Revenue | CN¥121.65m |
| Gross Profit | CN¥108.22m |
| Other Expenses | CN¥272.18m |
| Earnings | -CN¥163.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 47.08% |
| Net Profit Margin | -71.33% |
| Debt/Equity Ratio | 48.8% |
How did 300942 perform over the long term?
See historical performance and comparison